AHIP Statement for House Hearing on Antitrust Concerns and FDA Approval Process
posted by AHIP
on July 27, 2017
AHIP submitted a statement for the official record of a July 27, 2017 hearing in the House Judiciary Committee. Our statement raises concerns about anticompetitive strategies deployed by some drug manufacturers that increase prescription drug prices and costs by limiting competition for FDA-regulated products. We also address the consequences these tactics have on consumers and outline recommendations for fixing the prescription drug market and reducing prescription drug prices. Our recommendations focus on reducing barriers to the entry of generic drugs into the marketplace, revisiting and revising orphan drug incentives, and addressing the impact of drug coupons and co-pay card programs – and related charitable foundations – on overall pharmaceutical cost trends.